Breaking News Instant updates and real-time market news.

HON

Honeywell

, V

Visa

09:17
04/21/17
04/21
09:17
04/21/17
09:17

On The Fly: Pre-market Movers

UP AFTER EARNINGS: Honeywell (HON), up 3.1%... Visa (V), up 2.2%... Hawaiian Holdings (HA), up 4.7%... Stanley Black & Deckern (SWK), up 2.8%... KSU (KSU), up 1.6%... Rockwell Collins (COL), up just under 1%... General Electric (GE), up marginally. ALSO HIGHER: Ocwen Financial (OCN), up 13.3% after announcing it disputes allegations raised by state regulators and after being upgraded to Buy from Neutral at Compass Point... New Residential (NRZ), up 2.6% following Ocwen Financial's announcement and upgrade... Diana Shipping (DSX), up 5% after its 17.5M share Secondary priced at $4.00. DOWN AFTER EARNINGS: ManpowerGroup (MAN), down 1.2%... Mattel (MAT), down 6%... Manhattan Associates (MANH), down 5.3%. ALSO LOWER: Hasbro (HAS), down 1.6% after Mattel reported quarterly results... Adamis Pharmaceuticals (ADMP), down 18.2% after its 4.3M share Spot Secondary priced at $3.50.

HON

Honeywell

V

Visa

HA

Hawaiian Holdings

$51.90

1.4 (2.77%)

SWK

Stanley Black & Decker

KSU

Kansas City Southern

COL

Rockwell Collins

GE

General Electric

OCN

Ocwen

NRZ

New Residential

DSX

Diana Shipping

MAN

Manpower

MAT

Mattel

$25.21

0.1 (0.40%)

MANH

Manhattan Associates

$50.58

0.02 (0.04%)

HAS

Hasbro

$96.01

0.5 (0.52%)

ADMP

Adamis Pharmaceuticals

$4.40

-0.1 (-2.22%)

  • 21

    Apr

  • 21

    Apr

  • 21

    Apr

  • 21

    Apr

  • 21

    Apr

  • 21

    Apr

  • 24

    Apr

  • 24

    Apr

  • 26

    Apr

  • 03

    May

  • 03

    May

  • 04

    May

  • 09

    May

  • 09

    May

  • 10

    May

  • 11

    May

  • 18

    May

  • 18

    May

  • 24

    May

  • 22

    Jun

  • 22

    Jun

  • 21

    Apr

  • 21

    Apr

HON Honeywell

12/19/16
OPCO
12/19/16
NO CHANGE
Target $134
OPCO
Outperform
Honeywell price target raised to $134 from $122 at Oppenheimer
Oppenheimer analyst Christopher Glynn raised his price target for Honeywell to $134 from $122, citing its 2017 outlook as he believes quality of drivers are set to improve. He reiterates an Outperform rating on the shares.
12/13/16
UBSW
12/13/16
NO CHANGE
UBSW
Neutral
Earlier than expected Boeing 777 rate cut negative for suppliers, says UBS
UBS analyst David Strauss said that while Boeing (BA) had previously signaled a 777 production rate cut was coming, he thinks the now-announced cut to 5 planes per month in mid-2017 is 3 to 6 months earlier than expected. He sees the earlier than expected transition as having negative implications for key 777 suppliers, including B/E Aerospace (BEAV), GE (GE), Honeywell (HON), Spirit AeroSystems (SPR) and Triumph Group (TGI). Strauss keeps a Neutral rating on Boeing, as he believes 777X development will burn a couple billion per year with overall FCF declining during this period, but also said the company's 30% dividend increase and $14B buyback announcement signals strong confidence in its cash flow outlook.
02/21/17
JEFF
02/21/17
NO CHANGE
Target $141
JEFF
Buy
Honeywell price target raised to $141 from $133 at Jefferies
Jefferies analyst Howard Rubel raised his price target for Honeywell to $141 following a review of the company's annual filing. The 10-K highlights elements of profitability and cash flows, Rubel tells investors in a research note. He expects the non-U.S. business will continue to be more profitable show better growth. Rubel keeps a Buy rating on Honeywell.
03/02/17
OPCO
03/02/17
NO CHANGE
Target $148
OPCO
Outperform
Honeywell price target raised to $148 from $134 at Oppenheimer
Oppenheimer analyst Christopher Glynn raised his price target for Honeywell to $148 from $134 as OM track record exceeds new commitments, organic outlook appears conditioned by recent years' macro headwinds. Further, with defense spending set to turn and Honeywell indicating AM outgrowth of flight hours this year, the analyst thinks an upward tweak of Aero guide could materialize during 2017. He reiterates an Outperform rating on the shares.
V Visa

04/21/17
OPCO
04/21/17
NO CHANGE
Target $100
OPCO
Outperform
Visa price target raised to $100 from $95 at Oppenheimer
Oppenheimer analyst Glenn Greene raised his price target for Visa to $100 from $95 after the company reported strong upside Q2 results. The analyst reiterates an Outperform rating on the shares.
04/19/17
OPCO
04/19/17
NO CHANGE
OPCO
Oppenheimer bullish on Visa, MasterCard ahead of results
Oppenheimer analyst Glenn Greene reiterates Outperform ratings for MasterCard (MA) and Visa (V) and $120 and $95 price targets, respectively, heading into results. The analyst is encouraged by "solid" January intra-quarter volume growth, improving gas price trends, strong retail sales growth, and broadly positive card issuer trends. Further, Greene continues to believe that MasterCard and Visa are attractive at current levels, given their defensible market positions and strong long-term prospects. Nonetheless, he prefers Visa relative to MasterCard at present given the continuing U.S. volume boost from the Costco (COST)/USAA wins and JPMorgan Chase (JPM) Sapphire Reserve momentum, apparent conservative guidance, and Visa Europe accretion benefits.
04/21/17
BERN
04/21/17
NO CHANGE
BERN
Visa price target raised to $110 from $105 at Bernstein
Bernstein analyst Lisa Ellis says that Visa reported "strong" results, and the analyst expects the stock's positive momentum to continue going forward. She raised her price target on the shares to $110 from $105 and continues to identify the stock as her top pick.
04/21/17
FBCO
04/21/17
NO CHANGE
Target $105
FBCO
Outperform
Visa price target raised to $105 from $100 at Credit Suisse
Credit Suisse analyst Moshe Orenbuch raised his price target for Visa to $105 from $100 following a Q2 beat on higher revenues and lower taxes. The analyst reiterates an Outperform rating on the shares.
HA Hawaiian Holdings
$51.90

1.4 (2.77%)

04/21/17
04/21/17
UPGRADE

Buy
Hawaiian Holdings upgraded on valuation, fundamental strength at Buckingham
As previously reported, Buckingham upgraded Hawaiian Holdings to Buy from Neutral and raised its price target to $63 from $55. The firm said there is a valuation disconnect as shares are down 9% year-to-date and underlying fundamentals remain strong. Buckingham's analyst has reduced concerns about competitive capacity between Hawaii and Japan due to domestic momentum and international strength elsewhere and raised estimates saying revenue is trending wall above forecasts.
04/21/17
BUCK
04/21/17
UPGRADE
BUCK
Buy
Hawaiian Holdings upgraded to Buy from Neutral at Buckingham
02/09/17
02/09/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Viacom (VIA, VIAB) upgraded to Outperform from Market Perform at Wells Fargo with analyst Marci Ryvicker saying the company's first quarter results prove its turnaround is "real and likely to continue." The strategic plan put in place by CEO Bakish makes sense, Ryvicker tells investors in a research note. The analyst raised his price target range for the shares to $48-$50 from $38-$40. 2. Micron (MU) upgraded to Buy from Underperform at BofA/Merrill. 3. Sanofi (SNY) upgraded to Buy from Neutral at Natixis. 4. Hawaiian Holdings (HA) upgraded to Outperform from Peer Perform at Wolfe Research. 5. Baker Hughes (BHI) upgraded to Positive from Neutral at Susquehanna with analyst Charles Minervino citing the selloff in shares and its upside opportunity associated with a US spending upcycle, synergies from its joint-venture with General Electric (GE), and the growth opportunities that could develop from a partnership with a diversified global oilfield services company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/09/17
WOLF
02/09/17
UPGRADE
WOLF
Outperform
Hawaiian Holdings upgraded to Outperform from Peer Perform at Wolfe Research
SWK Stanley Black & Decker

01/30/17
01/30/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lionsgate (LGF.A, LGF.B) reinstated with an Overweight at JPMorgan. 2. Stanley Black & Decker (SWK) initiated with an Overweight at Barclays. 3. Viacom (VIAB, VIA) resumed with an Overweight at Morgan Stanley. 4. Castlight Health (CSLT) initiated with a Market Perform at Cowen. 5. SmartFinancial (SMBK) initiated with an Outperform at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/30/17
LEHM
01/30/17
INITIATION
Target $140
LEHM
Overweight
Stanley Black & Decker initiated with an Overweight at Barclays
Barclays analyst Robert Wertheimer started Stanley Black & Decker with an Overweight rating and $140 price target.
04/11/17
NOMU
04/11/17
INITIATION
Target $145
NOMU
Buy
Stanley Black & Decker initiated with a Buy at Nomura Instinet
Nomura Instinet analyst Michael Wood started Stanley Black & Decker with a Buy rating and $145 price target.
03/23/17
BARD
03/23/17
NO CHANGE
Target $147
BARD
Outperform
Stanley Black & Decker price target raised to $147 from $137 at Baird
Baird analyst Shannon O'Callaghan raised his price target on Stanley Black & Decker to $147 from $137 following the closing of the Craftsman and Newell deals. The analyst said the Newell deal enhances and strengthens the company's core strength in Tools & Storage while the Craftsman deal provides an opportunity for strong leverage. O'Callaghan reiterated his Outperform rating on Stanley shares.
KSU Kansas City Southern

03/15/17
WOLF
03/15/17
NO CHANGE
WOLF
Wolfe cuts Railroads to Market Weight, downgrades Norfolk Southern
Wolfe Research analyst Scott Group downgraded the Railroad sector to Market Weight from Overweight saying the risk/reward profiles are more balanced following the recent expansion of valuations. Group coupled the sector cut with a downgrade of Norfolk Southern (NSC) to Peer Perform from Outperform. The analyst thinks the company's operating ratio improvement could disappoint relative to CSX (CSX). He believes CSX has the best earnings story in the space under CEO Hunter Harrison.
03/13/17
WELS
03/13/17
INITIATION
WELS
Market Perform
Kansas City Southern initiated with a Market Perform at Wells Fargo
01/23/17
GHSC
01/23/17
DOWNGRADE
GHSC
Neutral
Kansas City Southern downgraded to Neutral from Accumulate at Seaport Global
Seaport Global analyst Mark Levin downgraded Kansas City Southern to Neutral saying there is too much uncertainty around US/Mexico trade policy to accurately forecast what earnings will look like in 2019 and beyond. The analyst acknowledges shares are "cheap" and maintained his $90 price target.
01/23/17
01/23/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Verizon (VZ) downgraded to Market Perform from Outperform at Wells Fargo with analyst Jennifer Fritzsche saying the stock's outperformance since U.S. presidential election is not sustainable given growth headwinds in 2017. 2. Qualcomm (QCOM) downgraded to Neutral from Buy at Nomura and to Underperform from Buy at CLSA. 3. Schlumberger (SLB) downgraded to Equal Weight from Overweight at Stephens with analyst Matthew Marietta saying he remains confident in Schlumberger's ability to benefit from the Cameron (CAM) integration, and its wide-ranging suite of products/services. 4. Unilever (UL, UN) downgraded to Equal Weight from Overweight at Barclays with analyst Simon Hales citing recent sector outperformance, currency uncertainty, and rising oil related input costs. 5. Kansas City Southern (KSU) downgraded to Neutral from Accumulate at Seaport Global with analyst Mark Levin saying there is too much uncertainty around U.S./Mexico trade policy to accurately forecast what earnings will look like in 2019 and beyond. The analyst acknowledges shares are "cheap" and maintained his $90 price target. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
COL Rockwell Collins

03/20/17
03/20/17
UPGRADE
Target $120

Outperform
Rockwell Collins upgraded to Outperform at Credit Suisse
As previously reported, Credit Suisse analyst Robert Spingarn upgraded Rockwell Collins (COL) to Outperform from Neutral as he expects a series of positive catalysts over the next 12 months. The analyst also sees a "strong pro-forma financial profile" with the ability to quickly delever, and says the B/E Aerospace (BEAV) acquisition is not priced in. Spingarn raised his price target on Rockwell Collins' to $120 from $92.
04/04/17
UBSW
04/04/17
NO CHANGE
Target $122
UBSW
Buy
Rockwell Collins price target raised to $122 from $108 at UBS
UBS analyst David Strauss raised his price target on Rockwell Collins (COL) to $122 from $108 on expectations the B/E Aerospace (BEAV) acquisition will close over the near-term, leading to higher earnings estimates and free cash flow. Strauss maintained his Buy rating on Rockwell Collins shares.
04/19/17
BARD
04/19/17
UPGRADE
Target $118
BARD
Outperform
Rockwell Collins upgraded to Outperform from Neutral at Baird
Baird analyst Peter Arment upgraded Rockwell Collins to Outperform from Neutral to reflect the recently closed acquisition of B/E Aerospace, which he views as having compelling accretion and cash flow generation. Arment believes investors should add or establish positions in Rockwell Collins below $100 per share and he raised his price target to $118 from $90.
03/20/17
FBCO
03/20/17
UPGRADE
FBCO
Outperform
Rockwell Collins upgraded to Outperform from Neutral at Credit Suisse
GE General Electric

04/10/17
FBRC
04/10/17
NO CHANGE
FBRC
FBR views Tesco as most likely takeover in Oilfield Services
FBR Capital analyst Thomas Curran says that within his Oilfield Services coverage, Tesco (TESO) has the highest probability of a straight acquisition. In GE Oil & Gas (GE) and Forum Energy (FET), Tesco has at least two potential strategic acquirers with "highly compelling logic," Curran tells investors in a research note. He believes a buyer could offer $10 per share. Tesco closed Friday at $7.30.
03/31/17
WBLR
03/31/17
NO CHANGE
WBLR
Outperform
General Electric shares set to move higher, says William Blair
William Blair analyst Nicholas Heymann believes shares of General Electric are set to move higher, not on management changes, but stronger fundamentals as the "external macro environment continues to improve." If GE achieves its more aggressive 2017 fundamental performance hurdles, the shares should be set to move steadily higher to the mid- to upper $30s, Heymann tells investors in a research note. The analyst sees potential upside to estimates from U.S. corporate tax reform and U.S. privately financed infrastructure modernization. He keeps an Outperform rating on GE shares.
03/28/17
JPMS
03/28/17
NO CHANGE
Target $27
JPMS
Underweight
General Electric price target lowered to $27 from $29 at JPMorgan
JPMorgan analyst C. Stephen Tusa lowered his price target for General Electric to $27 and keeps an Underweight rating on the shares. The sell-side bull thesis is shifting focus away from the $2.00 earnings per share target in 2018 to free cash flow, which is "seemingly appropriately," Tusa tells investors in a research note. The analyst views the emerging bull case on free cash flow as "overstated and not plausible." He notes his new $27 price target still implies a premium 4% free cash yield and "solid" 3.5% dividend yield.
03/13/17
JPMS
03/13/17
NO CHANGE
Target $29
JPMS
Underweight
JPMorgan says use GE rally as selling opportunity
JPMorgan analyst C. Stephen Tusa recommends using Friday's rally in General Electric shares as a selling opportunity. A possible CEO change does not change the analyst's view that GE is an expensive stock. Discussion of an activist, who owns less than 1% of the company, trying to make changes is a re-run of the case made two years ago, Tusa tells investors in a research note. The analyst does not see much a GE activist can do. The company's "stubbornly low growth and secular challenges embedded in end markets" can't be fixed by a CEO, the analyst contends. Tusa keeps an Underweight rating on shares of GE with a $29 price target. The stock rallied Friday to $30.28 after Fox Business reported that CEO Jeff Immelt is on the "hot seat" with activist Nelson Peltz.
OCN Ocwen

04/21/17
COMP
04/21/17
UPGRADE
Target $3.5
COMP
Buy
Ocwen upgraded to Buy from Neutral at Compass Point
Compass Point analyst Frederick Small upgraded Ocwen (OCN) to Buy from Neutral as he sees regulatory risk as mispriced following yesterday's CFPB lawsuit and states' cease-and-desist orders. He also does not think New Residential (NRZ) will transfer the majority of Ocwen's subservicing to another servicer, though he lowered his price target on Ocwen shares to $3.50 from $5.
04/20/17
KBWI
04/20/17
NO CHANGE
Target $5
KBWI
Market Perform
Immediate Ocwen impact from orders, lawsuit should be small, says Keefe Bruyette
Keefe Bruyette analyst Bose George noted that Ocwen is not currently purchasing servicing, so he believes the immediate impact from states issuing Cease-and-Desist orders and from the CFPB lawsuit against the company should be small. However, expenses could stay elevated and growth may be limited, even if it the company settles with NY DFS as expected, he added. George has a Market Perform rating and $5 price target on Ocwen shares, which are off their lows but remain down about 50% at $2.69.
04/21/17
COWN
04/21/17
NO CHANGE
COWN
CFPB, states not looking to put Ocwen out of business, says Cowen
Cowen analyst Jaret Seiberg does not believe the CFPB and the states are looking to put Ocwen out of business despite the latest litigation over how the company services mortgages. He believes forcing the movement of mortgages servicing is fraught with risk for the borrowers as payments can get misplaced, data can be lost, and modification efforts could be derailed. Seiberg said the mortgage servicing business is complex and technical and proving any violations is a low hurdle to clear. He believes the company's fight with NY regulators put them in the crosshairs of other states and that Ocwen "will always attract additional attention." He also noted there are supposedly 1,000 customers that claim they wrongfully had foreclosure proceedings initiated because of Ocwen errors, but based on previous history, he doubts that will end up being the case. Ocwen is not covered by Cowen research and the firm does not have a rating on the stock.
04/21/17
SBSH
04/21/17
NO CHANGE
SBSH
Buy
New Residential has protections investors are overlooking, says Citi
Citi analyst Michael Kaye views the Ocwen's (OCN) CFPB lawsuit and state cease and desist orders as a clear negative development for New Residential Investment (NRZ), but the analyst yesterday afternoon kept a Buy rating on the shares. The analyst believes Ocwen services about $120B of New Residential's $600B servicing portfolio. Kaye, however, thinks New Residential has some flexibility since Ocwen's Moody's servicer rating is below SQ3, which qualifies as a potential legal termination event. As such, New Residential has the legal right to move the servicing into its own name and let Ocwen stay on as a sub-servicer, which would provide additional protection, Kaye told investors in a research note. The company can also pull the servicing agreement from Ocwen to another sub-servicer, he adds. Kaye believes New Residential "has some built in protections that investors might be overlooking."
NRZ New Residential

04/20/17
SBSH
04/20/17
NO CHANGE
SBSH
New Residential shares defended at Citi
02/02/17
FBRC
02/02/17
NO CHANGE
Target $16.75
FBRC
Outperform
New Residential undervalued at current levels, says FBR Capital
FBR Capital analyst Jessica Levi-Ribner views shares of New Residential Investment as undervalued at current levels. The implied dividend yield of 12.5% should be safe in any interest rate environment, Levi-Ribner tells investors in research note, while pointing out the company is positioned for higher rates. The analyst keeps an Outperform rating on New Residential with a $16.75 price target following the company's Q4 results.
DSX Diana Shipping

12/09/16
12/09/16
NO CHANGE

Diana Shipping announces time charter contract for m/v San Francisco with Koch
Diana Shipping announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Koch Shipping Pte. Ltd., Singapore, for one of its Newcastlemax dry bulk vessels, "Hull No. H2548," to be named "San Francisco," which is currently under construction. The gross charter rate is $11,750 per day, minus a 5% commission paid to third parties, for a period of minimum twelve months to about sixteen months. The charter is expected to commence on January 6, 2017. This employment is anticipated to generate approximately $4.23M of gross revenue for the minimum scheduled period of the time charter.
01/27/17
NORD
01/27/17
UPGRADE
NORD
Buy
Diana Shipping upgraded to Buy from Hold at Nordea
04/07/17
JPMS
04/07/17
UPGRADE
Target $8
JPMS
Overweight
Diana Shipping upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Noah Parquette upgraded Diana Shipping (DSX) to Overweight saying the recovery in dry bulk shipping "is real and can be sustained for some time." The analyst sees "plenty of runway" for rates to continue to strengthen. He has an $8 price target for the shares. Parquette this morning also upgraded Golden Ocean (GOGL) to Overweight and doubled his price target for top pick Star Bulk Carriers (SBLK) to $20 from $10.
02/27/17
UBSW
02/27/17
NO CHANGE
UBSW
Sell
Drybulk shippers up too far, too fast since election, says UBS
UBS analyst Spiro Dounis was cautious on the Drybulk shipping sector, saying they many of the stocks in the sector have come too far, too fast since the election. He said the long-term fundamentals remains challenged as demand for iron ore and coal, two main drivers of larger vessel demand, are expected to decline. He said freight rates are off their historical lows but he would not view the current environment as strong and he expects several more years of losses before a return to profitability. Dounis maintained his Sell rating on both Diana Shipping (DSX) and Scorpio Bulkers (SALT).
MAN Manpower

02/01/17
FBCO
02/01/17
NO CHANGE
Target $100
FBCO
Neutral
Manpower price target raised to $100 from $80 at Credit Suisse
Credit Suisse analyst Anjaneya Singh raised his price target for Manpower to $100 from $80 after quarterly results. While there is much to appreciate about the company's results, the analyst sees several offsets. He reiterates a Neutral rating on the shares.
07/22/16
ARGS
07/22/16
NO CHANGE
ARGS
Manpower weakness creates buying opportunity, says Argus
After Manpower reported better than expected results, Argus says that the company's EPS is poised to increase significantly, amid "solid global economic conditions." The firm calls the stock "undervalued" and keeps a Buy rating on the shares.
08/17/16
DBAB
08/17/16
INITIATION
Target $77
DBAB
Hold
Manpower initiated with a Hold at Deutsche Bank
Target $77.
08/25/16
MACQ
08/25/16
INITIATION
Target $86
MACQ
Outperform
Manpower initiated with an Outperform at Macquarie
Macquarie analyst Hamzah Mazari initiated Manpower with an Outperform and $86 price target.
MAT Mattel
$25.21

0.1 (0.40%)

02/13/17
02/13/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Air Products (APD) reinstated with an Overweight at Barclays. 2. Hasbro (HAS) was initiated with a Buy at Goldman, while Mattel (MAT) was initiated with a Neutral. 3. Jagged Peak Energy (JAG) initiated with a Positive at Susquehanna. 4. Kimbell Royalty Partners (KRP) initiated with a Buy at Wunderlich. 5. HollyFrontier (HFC) reinstated with a Sell at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/13/17
GSCO
02/13/17
INITIATION
Target $27
GSCO
Neutral
Mattel initiated with a Neutral at Goldman
Goldman analyst Michael Ng initiated Mattel with a Neutral and a $27 price target. The analyst said Mattel is undergoing a turnaround in several of its core brands but consensus estimates are already looking for a meaningful recovery, creating increased risk.
02/08/17
PIPR
02/08/17
NO CHANGE
PIPR
Piper discusses resurfacing of Hasbro, Mattel deal speculation
Piper Jaffray analyst Stephanie Wissink points out that over her firm's 15 years of coverage, speculation of a merger between Hasbro (HAS) and Mattel (MAT) has surfaced several times. Hasbro's strong Q4 earnings report and share rally, in contrast with Mattel's negative Q4 preannouncement and pullback, has reignited the conjecture, Wissink tells investors in a research note. Economically a merger would create value, but a combination of the number two and three toy companies "would require significant evaluation from anti-trust authorities," the analyst writes. She believes a deal is possible if the Federal Trade Commission widens the boundaries around "youth entertainment & play," say to include video games, digital games and media. Hasbro closed yesterday up 67c to $94.98 while Mattel, after rallying in early trading, closed down 4c to $25.88. Wissink adds that she can find upwards of $500M of merger synergies if the two companies were to combine.
03/14/17
UBSW
03/14/17
NO CHANGE
UBSW
Buy
UBS discusses scenarios for hypothetical Mattel/Hasbro merger
UBS analyst Arpine Kocharyan noted market speculation about a potential merger of Hasbro (HAS) and Mattel (MAT). While admitting she has no view on the possibility of a deal happening, she does say there is large equity valuation gap between the two, with Mattel pricing in a potential dividend cut, and expressed her view that industry consolidation could pick up in 2017. Koocharyan maintains her Buy rating on Mattel and Neutral rating on Hasbro shares.
MANH Manhattan Associates
$50.58

0.02 (0.04%)

04/21/17
BNCH
04/21/17
DOWNGRADE
Target $48
BNCH
Hold
Manhattan Associates downgraded to Hold from Buy at Benchmark
Benchmark analyst Mark Schappel downgraded Manhattan Associates to Hold from Buy, noting that the company's cut to its 2017 revenue outlook was its third consecutive guide down. Schappel lowered his price target on Manhattan Associates shares to $48 from $65.
02/01/17
BNCH
02/01/17
NO CHANGE
Target $65
BNCH
Buy
Manhattan Associates price target lowered to $65 from $71 at Benchmark
Benchmark analyst Mark Schappel acknowledges he considered stepping aside with a downgrade of Manhattan Associates after the company's earnings report and "meaningfully lower" revenue outlook for 2017, but he believes the services business will bottom in Q1, allowing for a resumption of growth in the second half of the year if management executes. He keeps a Buy rating on Manhattan Associates shares, but cut his price target to $65 from $71 on the stock.
01/09/17
01/09/17
DOWNGRADE

Market Perform
Manhattan Associates downgraded on headwinds at Raymond James
As previously reported, Raymond James downgraded Manhattan Associates to Market Perform from Outperform. Analyst Terry Tillman said checks indicate solid software activity but pockets of weakness in the retail segment and some large deal potential deferral activity that could impact both software license and professional services revenue and linger into 2017. Furthermore, recent negative headlines out of big box retailers and others too heavily geared towards brick and mortar while lacking an adequate omni-channel strategy, could potentially impact sales for the company, the analyst wrote.
01/26/17
BMUR
01/26/17
NO CHANGE
Target $75
BMUR
Buy
Manhattan Associates services weakness likely to linger, says Brean Capital
Brean Capital analyst Yun Kim said his most recent channel checks for Manhattan Associates indicate services weakness remains and may linger. He said the checks also indicate the issues behind the weakness are temporary and not reflective of any decline in fundamentals. Kim believes the risk/reward at current valuation levels favor the long-term opportunity around the Omni-channel secular trend, which should offset the risks related to the current weakness. Kim reiterated his Buy rating and $75 price target on Manhattan Associates shares.
HAS Hasbro
$96.01

0.5 (0.52%)

04/04/17
RILY
04/04/17
INITIATION
Target $111
RILY
Neutral
Hasbro initiated with a Neutral at B. Riley
B. Riley analyst Linda Bolton Weiser started Hasbro with a Neutral rating and $111 price target.
04/04/17
04/04/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Snap (SNAP) initiated with a Neutral due to valuation at BTIG. 2. HP Enterprise (HPE) initiated with a Hold at Berenberg. 3. Hasbro (HAS) initiated with a Neutral at B. Riley. 4. Lionsgate (LGF.A, LGF.B) initiated with a Buy at Canaccord. 5. Vistra Energy (VSTE) initiated with a Peer Perform at Wolfe Research. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ADMP Adamis Pharmaceuticals
$4.40

-0.1 (-2.22%)

01/24/17
MAXM
01/24/17
NO CHANGE
Target $10
MAXM
Buy
Adamis undervalued if able to take just 10% of EpiPen market, says Maxim
After privately-held Kaleo announced a "complex pricing strategy" for their EpiPen-like device, Auvi-Q, which is returning to the market, Maxim analyst Jason Kolbert said he views Adamis' (ADMP) PFS to be a better, more user friendly product than Mylan's (MYL) EpiPen, Impax Labs' (IPXL) Adrenaclick and Kaleo's AuviQ. If Adamis can acquire just 10% market share, which he believes is at the low end, the shares are undervalued, Kolbert tells investors. He keeps a Buy rating and $10 price target on Adamis shares.
12/20/16
RILY
12/20/16
INITIATION
Target $5
RILY
Buy
Adamis Pharmaceuticals initiated with a Buy at B. Riley
B. Riley analyst Greg Chodaczek started Adamis Pharmaceuticals with a Buy rating and $5 price target. The company has three respiratory products in its development pipeline, representing a $20B opportunity, the analyst contends.
12/19/16
MAXM
12/19/16
NO CHANGE
Target $10
MAXM
Buy
Adamis resubmission sets up mid-year PDUFA for generic EpiPen, says Maxim
Maxim analyst Jason Kolbert said Adamis Pharmaceuticals' (ADMP) resubmission of its New Drug Application for its epinephrine pre-filled syringe, a generic version of Mylan's (MYL) EpiPen, addresses all the issues in the FDA Complete Response Letter and triggers a 30 day review to "accept" the filing, which should be followed by a six month PDUFA date and approval by June of next year, he believes. Adamis' version is more user friendly, design wise, than Mylan's generic and the market opportunity is large, said Kolbert, who thinks that this can become a significant product for the company "even with just moderate market share assumptions." He keeps a Buy rating and $10 price target on Adamis, which he sees as "poised for a breakout" in 2017.

TODAY'S FREE FLY STORIES

AAPL

Apple

$146.28

0.65 (0.45%)

, AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

13:47
06/24/17
06/24
13:47
06/24/17
13:47
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$146.28

0.65 (0.45%)

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

GOOG

Alphabet

$965.59

8.5 (0.89%)

MSFT

Microsoft

$71.21

0.95 (1.35%)

IBM

IBM

$154.11

-0.29 (-0.19%)

MA

MasterCard

$124.01

0.71 (0.58%)

ORCL

Oracle

$50.95

0.65 (1.29%)

VMW

VMware

$90.92

0.48 (0.53%)

INTC

Intel

$34.19

-0.17 (-0.49%)

AKAM

Akamai

$51.30

1.28 (2.56%)

SAP

SAP

$107.48

0.42 (0.39%)

QCOM

Qualcomm

$56.91

0.44 (0.78%)

ADBE

Adobe

$145.41

1.72 (1.20%)

ACN

Accenture

$122.74

0.66 (0.54%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

LPNT

LifePoint

$65.50

-1.6 (-2.38%)

CYH

Community Health

$9.33

0.06 (0.65%)

THC

Tenet

$18.52

-0.38 (-2.01%)

HCA

HCA Holdings

$86.24

0.1 (0.12%)

UHS

Universal Health

$115.43

0.22 (0.19%)

AET

Aetna

$152.10

-0.88 (-0.58%)

WCG

WellCare

$183.28

-0.32 (-0.17%)

CI

Cigna

$169.61

-1.07 (-0.63%)

HUM

Humana

$238.42

1.42 (0.60%)

ANTM

Anthem

$190.17

-3.19 (-1.65%)

HNT

Health Net

CNC

Centene

$84.15

1.15 (1.39%)

MOH

Molina Healthcare

$71.33

0.02 (0.03%)

UNH

UnitedHealth

$185.25

-1.25 (-0.67%)

REGN

Regeneron

$517.33

-9.2 (-1.75%)

CELG

Celgene

$134.31

0.63 (0.47%)

VRTX

Vertex

$133.50

-2.03 (-1.50%)

ALXN

Alexion

$126.07

-0.16 (-0.13%)

BIIB

Biogen

$280.32

-0.25 (-0.09%)

AMGN

Amgen

$172.50

-1.32 (-0.76%)

X

U.S. Steel

$22.25

1.18 (5.60%)

AKS

AK Steel

$6.65

0.35 (5.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 29

    Jun

  • 06

    Jul

  • 12

    Jul

  • 13

    Jul

  • 18

    Jul

  • 19

    Jul

  • 19

    Jul

  • 20

    Jul

  • 25

    Jul

  • 25

    Jul

  • 30

    Jul

  • 02

    Aug

  • 14

    Aug

  • 23

    Oct

  • 03

    Feb

ARQL

ArQule

$1.17

0.03 (2.63%)

, NLNK

NewLink Genetics

$7.36

-0.04 (-0.54%)

04:55
06/24/17
06/24
04:55
06/24/17
04:55
Conference/Events
European Hematology Association to hold a conference »

22nd Congress of the EHA…

ARQL

ArQule

$1.17

0.03 (2.63%)

NLNK

NewLink Genetics

$7.36

-0.04 (-0.54%)

BLUE

bluebird bio

$112.00

-6.5 (-5.49%)

XLRN

Acceleron

$34.10

0.15 (0.44%)

BLCM

Bellicum Pharmaceuticals

$13.39

-0.59 (-4.22%)

CRSP

CRISPR Therapeutics

$16.44

0.3 (1.86%)

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

CELG

Celgene

$134.31

0.63 (0.47%)

STML

Stemline

$9.10

0.6 (7.06%)

CTIX

Cellceutix

KPTI

Karyopharm

$9.97

0.01 (0.10%)

RARX

RA Pharmaceuticals

$23.01

0.01 (0.04%)

CDTX

Cidara Therapeutics

$6.70

-0.2 (-2.90%)

GBT

Global Blood Therapeutics

$29.85

0.6 (2.05%)

PTLA

Portola Pharmaceuticals

$56.06

17.81 (46.56%)

TGTX

TG Therapeutics

$11.95

-0.05 (-0.42%)

VSTM

Verastem

$2.32

-0.06 (-2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 24

    Jun

  • 27

    Jun

  • 29

    Jun

  • 29

    Jun

  • 06

    Jul

  • 11

    Jul

  • 26

    Sep

HIMX

Himax

$8.17

-0.02 (-0.24%)

04:55
06/24/17
06/24
04:55
06/24/17
04:55
Conference/Events
Himax management to meet with Roth Captial »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

ANTM

Anthem

$190.17

-3.19 (-1.65%)

18:58
06/23/17
06/23
18:58
06/23/17
18:58
Periodicals
Anthem to pay $115M to settle data breach lawsuits, Reuters reports »

Anthem has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVU

Supervalu

$2.94

-0.04 (-1.34%)

18:26
06/23/17
06/23
18:26
06/23/17
18:26
Hot Stocks
Supervalu completes acquisition of Unified Grocers »

Supervalu announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GILD

Gilead

$70.52

0.04 (0.06%)

18:14
06/23/17
06/23
18:14
06/23/17
18:14
Periodicals
Gilead no longer a 'value trap,' Barron's reports »

Consistent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 06

    Jul

SONA

Southern National Bancorp

$17.21

0.11 (0.64%)

, EVBS

Eastern Virginia Bankshares

$11.01

0.14 (1.29%)

18:07
06/23/17
06/23
18:07
06/23/17
18:07
Hot Stocks
Southern National Bancorp, Eastern Virginia Bankshares complete merger »

Southern National Bancorp…

SONA

Southern National Bancorp

$17.21

0.11 (0.64%)

EVBS

Eastern Virginia Bankshares

$11.01

0.14 (1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAC

IAC

$104.84

0.3 (0.29%)

17:56
06/23/17
06/23
17:56
06/23/17
17:56
Hot Stocks
IAC will not pursue plan to create new class of non-voting stock »

IAC's Board of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

EGL

Engility

$27.37

0.26 (0.96%)

17:50
06/23/17
06/23
17:50
06/23/17
17:50
Hot Stocks
Engility to eliminate position of president, COO »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

ADM

Archer Daniels

$41.16

0.13 (0.32%)

17:48
06/23/17
06/23
17:48
06/23/17
17:48
Hot Stocks
ADM Animal Nutrition recalls Rough-N-Ready cattle feed over monensin concerns »

ADM Animal Nutrition, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOYA

Voya Financial

$35.24

0.03 (0.09%)

17:30
06/23/17
06/23
17:30
06/23/17
17:30
Syndicate
Breaking Syndicate news story on Voya Financial »

Voya Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBTX

Independent Bank

$54.85

-1.1 (-1.97%)

, TBK

Triumph Bancorp

17:19
06/23/17
06/23
17:19
06/23/17
17:19
Hot Stocks
Independent Bank to sell nine Colorado branches to TBK Bank »

Independent Bank (IBTX)…

IBTX

Independent Bank

$54.85

-1.1 (-1.97%)

TBK

Triumph Bancorp

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

WUBA

58.com

$43.30

0.87 (2.05%)

17:11
06/23/17
06/23
17:11
06/23/17
17:11
Hot Stocks
Breaking Hot Stocks news story on 58.com »

General Atlantic reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOXA

21st Century Fox

$27.19

0.22 (0.82%)

, LGF.B

Lionsgate

$25.38

0.34 (1.36%)

17:10
06/23/17
06/23
17:10
06/23/17
17:10
Hot Stocks
Box Office Battle: 'Transformers' expected to top 'Cars 3,' 'Wonder Woman' »

Viacom (VIA, VIAB)…

FOXA

21st Century Fox

$27.19

0.22 (0.82%)

LGF.B

Lionsgate

$25.38

0.34 (1.36%)

DIS

Disney

$104.36

0.14 (0.13%)

VIAB

Viacom

$34.11

-0.01 (-0.03%)

LGF.A

Lionsgate

$27.07

0.31 (1.16%)

VIA

Viacom

$39.15

0.1 (0.26%)

SNE

Sony

$38.52

0.11 (0.29%)

FOX

21st Century Fox

$26.93

0.3 (1.13%)

TWX

Time Warner

$99.70

0.3 (0.30%)

CMCSA

Comcast

$39.50

-0.44 (-1.10%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 27

    Jul

  • 03

    Aug

  • 08

    Aug

NVUS

Novus Therapeutics

$6.00

-0.04 (-0.66%)

17:07
06/23/17
06/23
17:07
06/23/17
17:07
Syndicate
Breaking Syndicate news story on Novus Therapeutics  »

Novus Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDXG

Interpace Diagnostics

$0.88

0.03 (3.53%)

17:05
06/23/17
06/23
17:05
06/23/17
17:05
Hot Stocks
Breaking Hot Stocks news story on Interpace Diagnostics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNR

Monmouth Real Estate

$14.95

0.26 (1.77%)

17:02
06/23/17
06/23
17:02
06/23/17
17:02
Hot Stocks
Monmouth Real Estate acquires building in Texas for $50.6M »

Monmouth Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Aug

ARCW

ARC Group

$3.55

0.15 (4.41%)

17:01
06/23/17
06/23
17:01
06/23/17
17:01
Hot Stocks
ARC Group names Drew Kelley as Interim CEO, effective July 1 »

ARC Group Worldwide…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAVM

PAVmed

$4.41

-0.08 (-1.78%)

16:55
06/23/17
06/23
16:55
06/23/17
16:55
Syndicate
PAVmed announces effectiveness of Form S-1 resale registration statement »

PAVmed announced that on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MFSF

MutualFirst Financial

$36.15

0.9 (2.55%)

16:48
06/23/17
06/23
16:48
06/23/17
16:48
Hot Stocks
MutualFirst Financial senior executives enter 10b5-1 trading plans »

On June 23, David Heeter,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$32.10

0.25 (0.78%)

16:46
06/23/17
06/23
16:46
06/23/17
16:46
Hot Stocks
Cisco CEO Charles Robbins enters 10b5-1 trading plan »

On June 21, Charles…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 12

    Jul

  • 12

    Jul

  • 13

    Jul

  • 16

    Aug

SITO

SITO Mobile

$3.66

0.02 (0.55%)

16:43
06/23/17
06/23
16:43
06/23/17
16:43
Hot Stocks
SITO Mobile chairman Paul Pressler resigns »

Effective as of June 23,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$517.33

-9.2 (-1.75%)

, CELG

Celgene

$134.31

0.63 (0.47%)

16:41
06/23/17
06/23
16:41
06/23/17
16:41
General news
S&P sees mild weekly gain, Nasdaq outperforms as biotech shines »

The S&P finished the…

REGN

Regeneron

$517.33

-9.2 (-1.75%)

CELG

Celgene

$134.31

0.63 (0.47%)

GILD

Gilead

$70.54

0.06 (0.09%)

BIIB

Biogen

$280.32

-0.25 (-0.09%)

VRTX

Vertex

$133.50

-2.03 (-1.50%)

AMGN

Amgen

$172.50

-1.32 (-0.76%)

ABBV

AbbVie

$72.64

-0.54 (-0.74%)

ALXN

Alexion

$126.07

-0.16 (-0.13%)

BA

Boeing

$202.23

2.79 (1.40%)

ORCL

Oracle

$50.95

0.65 (1.29%)

EQT

EQT Corporation

$56.19

4.16 (8.00%)

RICE

Rice Energy

$25.65

1.62 (6.74%)

SYK

Stryker

$141.12

-0.1 (-0.07%)

NVDQ

Novadaq

$11.78

-0.02 (-0.17%)

PRXL

Parexel

$86.80

-0.31 (-0.36%)

LH

LabCorp

$151.62

1.28 (0.85%)

ICLR

ICON plc

$96.37

-0.26 (-0.27%)

NKE

Nike

$52.85

0.45 (0.86%)

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

INTC

Intel

$34.19

-0.17 (-0.49%)

AMD

AMD

$14.15

-0.23 (-1.60%)

LZB

La-Z-Boy

$32.30

0.7 (2.22%)

RHT

Red Hat

$99.42

0.54 (0.55%)

AAL

American Airlines

$48.63

-0.34 (-0.69%)

HCA

HCA Holdings

$86.24

0.1 (0.12%)

LPNT

LifePoint

$65.50

-1.6 (-2.38%)

THC

Tenet

$18.52

-0.38 (-2.01%)

SCS

Steelcase

$13.65

-0.45 (-3.19%)

ACN

Accenture

$122.74

0.66 (0.54%)

BBBY

Bed Bath & Beyond

$29.65

-4.09 (-12.12%)

BBRY

BlackBerry

$9.71

-1.35 (-12.21%)

BAC

Bank of America

$22.82

-0.11 (-0.48%)

C

Citi

$63.41

-0.21 (-0.33%)

GS

Goldman Sachs

$217.19

-2.58 (-1.17%)

JPM

JPMorgan

$86.86

-0.16 (-0.18%)

MS

Morgan Stanley

$43.69

-0.92 (-2.06%)

WFC

Wells Fargo

$52.45

-0.04 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 23

    Jun

  • 26

    Jun

  • 26

    Jun

  • 26

    Jun

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 06

    Jul

  • 07

    Jul

  • 13

    Jul

  • 14

    Jul

  • 14

    Jul

  • 18

    Jul

  • 19

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

  • 30

    Jul

  • 14

    Aug

  • 29

    Aug

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 23

    Oct

  • 14

    Nov

  • 15

    Jan

  • 03

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

16:39
06/23/17
06/23
16:39
06/23/17
16:39
General news
Moody's raises Greece rating to Caa2 from Caa3, outlook to positive from stable »

Moody's has upgraded…

CFCO

CF Corporation

$11.42

-0.04 (-0.35%)

16:38
06/23/17
06/23
16:38
06/23/17
16:38
Hot Stocks
Breaking Hot Stocks news story on CF Corporation »

Mason Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.